Hemp-Derived Intoxicants Regulation: Federal and State Policy Guide

Executive Summary

Hemp-derived intoxicants—psychoactive cannabinoids synthesized or extracted from legal hemp—occupy a regulatory gray zone that has created a multi-billion-dollar unregulated market selling products in gas stations, convenience stores, and online retailers nationwide. The 2018 Farm Bill legalized hemp containing no more than 0.3% delta-9 THC by dry weight, inadvertently opening the door for manufacturers to produce delta-8 THC, delta-10 THC, THC-O, THCP, and other novel cannabinoids through chemical conversion processes. These products deliver intoxicating effects comparable to traditional marijuana but exist outside state-licensed cannabis programs, raising urgent questions about consumer safety, product testing, age verification, and federal enforcement authority. As of June 2026, at least 22 states have enacted restrictions or outright bans on hemp-derived intoxicants, while the DEA and FDA have issued conflicting guidance on their legal status. The regulatory vacuum has attracted both legitimate hemp operators and bad actors, with products ranging from rigorously tested formulations to contaminated goods containing residual solvents, heavy metals, and synthetic additives. Political alliances spanning libertarian-leaning Republicans, hemp industry lobbyists, and some Trump administration officials have complicated federal enforcement efforts, while state-licensed cannabis operators and public health advocates push for comprehensive regulation.

Why This Matters

The hemp-derived intoxicants market reached an estimated $2.8 billion in annual sales by 2025, rivaling legal cannabis markets in several states while operating without the testing, labeling, or age-verification requirements that govern licensed dispensaries. The regulatory chaos affects multiple stakeholder groups with billions of dollars and public health outcomes at stake. State-licensed cannabis operators face direct competition from untaxed, untested hemp products sold at lower prices in convenience stores, undermining the economic viability of regulated markets that investors poured $15 billion into building since 2014. Licensed cultivators in California, Colorado, and Michigan reported 15-25% revenue declines in 2024-2025 attributed partly to hemp-derived product competition. Public health officials express concern about products marketed to minors through candy-like packaging, inadequate potency labeling, and lack of childproof packaging requirements. Poison control centers reported a 340% increase in pediatric exposures to hemp-derived edibles between 2021 and 2025, according to data from the American Association of Poison Control Centers. Emergency department visits for acute cannabinoid intoxication rose 180% in states without hemp intoxicant restrictions during the same period. The hemp farming industry, valued at $824 million in 2025, depends heavily on cannabinoid extraction revenue, with approximately 60% of hemp biomass cultivated specifically for cannabinoid production rather than fiber or seed applications. Farmers in Kentucky, North Carolina, and Tennessee built business models around supplying processors who convert CBD-rich hemp into delta-8 THC and related compounds through isomerization chemistry. Federal agencies face jurisdictional questions with profound implications for the Controlled Substances Act framework. If hemp-derived THC isomers fall outside DEA scheduling authority due to the Farm Bill's hemp exemption, it creates a precedent-setting gap in federal drug control that could extend to other substance categories.

Background and History

The 2018 Farm Bill Hemp Provision

The Agricultural Improvement Act of 2018, signed December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act by defining it as cannabis containing not more than 0.3% delta-9 tetrahydrocannabinol on a dry weight basis. The legislation, championed by Senate Majority Leader Mitch McConnell of Kentucky, aimed to revitalize American hemp farming for industrial fiber, seed oil, and CBD extraction. Section 10113 of the Farm Bill amended the Agricultural Marketing Act of 1946 to establish hemp as an agricultural commodity under USDA oversight rather than DEA control. The 0.3% delta-9 THC threshold originated from a 1976 taxonomic paper by Canadian researchers Ernest Small and Arthur Cronquist, who acknowledged the distinction was arbitrary and chosen for practical classification rather than pharmacological significance. Congress adopted this threshold without anticipating that chemists would exploit the narrow definition by converting legal CBD into intoxicating THC isomers not explicitly named in the statute. The Farm Bill transferred regulatory authority over hemp cultivation to the USDA, which published final rules October 31, 2019, establishing state and tribal plan approval processes, testing protocols, and compliance requirements. Critically, the USDA rules addressed only cultivation and focused exclusively on delta-9 THC content, creating no framework for regulating downstream processing or finished hemp products.

The Delta-8 THC Emergence (2019-2021)

Delta-8 tetrahydrocannabinol, a minor cannabinoid occurring naturally in cannabis at concentrations below 1%, became commercially viable in 2019 when processors developed efficient methods to convert CBD isolate into delta-8 THC through acid-catalyzed isomerization. The process typically involves dissolving CBD in a nonpolar solvent, adding an acid catalyst such as hydrochloric acid or p-toluenesulfonic acid, heating the mixture, then neutralizing and purifying the resulting delta-8 THC. The first delta-8 THC products appeared in hemp retail stores in Florida and Texas during late 2019, marketed as legal alternatives to marijuana in states without adult-use programs. By mid-2020, delta-8 vape cartridges, gummies, and tinctures proliferated across convenience stores, smoke shops, and online retailers, with manufacturers claiming the products derived from legal hemp and therefore fell outside state marijuana laws. The COVID-19 pandemic accelerated delta-8 market growth as consumers sought legal intoxicants during lockdowns and economic uncertainty. Industry analysts estimated delta-8 sales reached $2 billion in 2021, with over 5,000 brands entering the market. The rapid expansion occurred entirely outside regulatory oversight, with no testing requirements, potency limits, or manufacturing standards.

DEA Interim Final Rule (August 2020)

On August 21, 2020, the DEA published an Interim Final Rule implementing the Farm Bill's hemp provisions by creating a new DEA drug code (7350) for hemp and confirming that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances." The rule stated that "for synthetically derived THC, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance." The DEA's position that synthetically derived THC remains Schedule I regardless of its source created immediate legal ambiguity about delta-8 THC produced through chemical conversion of hemp-derived CBD. Hemp industry attorneys argued the products qualified as hemp derivatives exempt from scheduling, while the DEA maintained that chemical synthesis placed them under Schedule I. The agency provided no enforcement guidance, leaving state and local authorities uncertain about their authority to regulate or prohibit the products.

State Regulatory Responses (2020-2023)

Alaska became the first state to explicitly ban delta-8 THC in July 2020, with the Alcohol and Marijuana Control Office issuing guidance that all THC isomers remained controlled substances under state law regardless of source material. Colorado followed in September 2020, with the Marijuana Enforcement Division clarifying that delta-8 THC required production within the state's licensed marijuana system. By December 2023, 18 states had enacted restrictions or prohibitions on hemp-derived intoxicants through legislative action, emergency rules, or attorney general opinions. Approaches varied widely: some states banned specific compounds by name (delta-8, delta-10, THC-O), others prohibited all "chemically modified" or "synthetically derived" cannabinoids, while a few established regulatory frameworks allowing hemp intoxicants with testing and labeling requirements. Texas presented a notable case study in regulatory confusion. The state's 2019 hemp law legalized hemp and hemp products containing less than 0.3% delta-9 THC, which manufacturers interpreted as permitting delta-8 products. The Texas Department of State Health Services attempted to ban delta-8 in October 2021, but a Travis County district court issued a temporary injunction in February 2022, finding the agency exceeded its authority. As of June 2026, delta-8 THC remains legal in Texas pending ongoing litigation, making it the largest unregulated hemp intoxicant market with estimated annual sales exceeding $500 million.

Novel Cannabinoid Proliferation (2021-2024)

As states began restricting delta-8 THC, manufacturers introduced additional hemp-derived intoxicants to circumvent specific compound bans. THC-O acetate, produced by reacting delta-8 or delta-9 THC with acetic anhydride, appeared in products during 2021 marketed as more potent than delta-8. Delta-10 THC, another isomer produced through CBD conversion, entered the market in late 2021. THCP (tetrahydrocannabiphorol), a naturally occurring cannabinoid with higher CB1 receptor affinity than delta-9 THC, became available in synthesized form during 2022. HHC (hexahydrocannabinol), produced by hydrogenating THC, gained market share in 2023 as manufacturers sought compounds not explicitly named in state bans. The FDA issued warning letters to six companies in February 2023 for marketing THC-O products, stating that THC-O acetate did not occur naturally in cannabis and therefore did not qualify as a hemp derivative under the Farm Bill. The agency noted that acetic anhydride is a DEA List I chemical due to its use in heroin synthesis, raising additional concerns about manufacturing processes.

USDA and FDA Jurisdictional Gaps

The USDA maintained its regulatory authority extended only to hemp cultivation, not processing or finished products. In a May 2022 statement, the agency clarified that "USDA has no authority to regulate or prohibit the sale of hemp-derived products, including those containing delta-8 THC or other cannabinoids." The FDA asserted authority over hemp-derived products as food, dietary supplements, or drugs under the Federal Food, Drug, and Cosmetic Act, but devoted minimal enforcement resources to the issue. Between 2019 and 2025, the FDA issued only 47 warning letters to hemp intoxicant manufacturers, compared to thousands of products on the market. The agency's primary focus remained on CBD products making therapeutic claims rather than intoxicating cannabinoids. This jurisdictional vacuum left state and local authorities as the primary regulators, creating a patchwork of conflicting rules that manufacturers exploited through interstate commerce and online sales.

Key Players

Drug Enforcement Administration

The DEA maintains that synthetically derived THC remains Schedule I regardless of source material, but has conducted minimal enforcement against hemp-derived intoxicant manufacturers or retailers as of June 2026. The agency's August 2020 Interim Final Rule established its legal position, but subsequent enforcement actions focused on traditional marijuana trafficking rather than hemp-derived products. DEA Administrator Anne Milgram testified before Congress in March 2024 that the agency lacked resources to pursue thousands of hemp retailers and that state-level enforcement would be more effective. Internal DEA guidance obtained through FOIA requests revealed the agency prioritized fentanyl, methamphetamine, and cocaine trafficking over hemp-derived cannabinoids.

Food and Drug Administration

The FDA's Center for Food Safety and Applied Nutrition oversees hemp-derived products marketed as food or dietary supplements, while the Center for Drug Evaluation and Research handles products making therapeutic claims. The agency issued a statement in May 2023 warning that delta-8 THC products had not been evaluated for safety and that manufacturing processes could introduce harmful contaminants. FDA testing of delta-8 products in 2023-2024 found that 18 of 27 samples contained residual solvents above safe limits, 11 contained heavy metals including lead and arsenic, and 8 contained delta-9 THC concentrations exceeding 0.3%, making them federally illegal marijuana products. The agency published these results but took no enforcement action against specific manufacturers.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a hemp industry trade association, has advocated for federal regulation of hemp-derived intoxicants rather than prohibition. The organization supported the Hemp Production and the Farm Bill Act introduced in 2024, which would have established FDA oversight of hemp-derived cannabinoid products with testing and labeling requirements. The Roundtable represents primarily CBD manufacturers who view unregulated intoxicating products as threatening the broader hemp industry's reputation and market access. The organization's president, Jonathan Miller, stated in congressional testimony that "responsible regulation protects consumers while preserving hemp farmers' market opportunities."

Hemp Industry Processors

Companies including Hometown Hero, 3Chi, and Delta Effex emerged as major delta-8 manufacturers, with combined revenues estimated at $400 million annually. These processors source CBD isolate from hemp farmers, perform chemical conversions in facilities ranging from sophisticated laboratories to makeshift operations, then distribute finished products through wholesale networks. 3Chi, based in Indiana, became the largest delta-8 brand by market share in 2023, selling products through over 15,000 retail locations nationwide. The company implemented voluntary third-party testing and published certificates of analysis, positioning itself as a quality leader in an unregulated market.

State-Licensed Cannabis Operators

Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have lobbied state legislatures to ban or strictly regulate hemp-derived intoxicants, arguing that unregulated products undermine legal cannabis markets. The Cannabis Trade Federation, representing licensed operators, supported state-level prohibitions in Michigan, Rhode Island, and New York. Licensed operators face effective tax rates of 40-70% when accounting for 280E limitations, state excise taxes, and sales taxes, while hemp-derived products avoid marijuana-specific taxation. This creates price disparities of 30-50% for comparable intoxicating products, driving consumers to unregulated channels.

Public Health Advocates

The American Academy of Pediatrics, American Medical Association, and Association of State and Territorial Health Officials issued a joint statement in September 2024 calling for federal regulation of hemp-derived intoxicants with age restrictions, potency limits, and childproof packaging requirements. The organizations cited poison control data showing pediatric exposures and emergency department visits. Smart Approaches to Marijuana (SAM), an organization opposing cannabis legalization, advocated for DEA enforcement against delta-8 manufacturers and state-level prohibitions. SAM president Kevin Sabet testified before state legislatures that hemp-derived intoxicants represented "a massive regulatory failure putting children at risk."

Political Allies in Federal Government

According to reporting from The New York Times in June 2026, hemp industry representatives cultivated relationships with officials in the Trump administration who supported limiting federal regulation of hemp-derived products. These alliances complicated DEA and FDA enforcement efforts by creating political pressure to avoid aggressive action against an industry with support among Republican lawmakers and libertarian-leaning constituencies. The hemp industry contributed $8.4 million to federal candidates during the 2024 election cycle, according to Federal Election Commission records, with 68% directed to Republican candidates. Industry lobbyists emphasized hemp farming's economic importance in rural communities and framed regulation as government overreach.

Legal and Regulatory Framework

Federal Statutes

The Controlled Substances Act, 21 U.S.C. § 801 et seq., establishes the federal drug scheduling system, with Schedule I reserved for substances with high abuse potential and no accepted medical use. Tetrahydrocannabinols were placed in Schedule I in 1970, with the definition codified at 21 CFR § 1308.11(d)(31) as "tetrahydrocannabinols, meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis." The Agricultural Improvement Act of 2018, Public Law 115-334, amended the Controlled Substances Act by adding Section 802(16)(B), which excludes hemp from the definition of marijuana. Hemp is defined as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The critical legal question centers on whether chemically converted cannabinoids qualify as "derivatives" of hemp or as "synthetically derived tetrahydrocannabinols" that remain Schedule I. The Farm Bill does not define "derivative" or "synthetically derived," creating ambiguity that courts have not definitively resolved as of June 2026.

DEA Regulatory Positions

The DEA's August 21, 2020 Interim Final Rule, 85 Fed. Reg. 51639, states: "All synthetically derived tetrahydrocannabinols remain schedule I controlled substances... For synthetically derived THC, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance. All synthetically derived THC is controlled in schedule I." The DEA defined "synthetically derived" in a May 2021 letter to the Alabama Board of Pharmacy as THC "created by a chemical reaction that changes the molecular structure of any starting material substance, which itself could be a natural or synthetic substance." This definition would encompass delta-8 THC produced through acid-catalyzed isomerization of CBD, but the DEA has not issued formal guidance applying this interpretation to hemp-derived products or initiated enforcement actions testing the legal theory in court.

FDA Authority and Positions

The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., grants FDA authority over food, dietary supplements, drugs, and cosmetics in interstate commerce. The agency's position, articulated in a May 4, 2023 statement, holds that delta-8 THC products marketed for human consumption require FDA approval as food additives or drugs. Section 301(ll) of the FD&C Act, added by the 2018 Farm Bill, prohibits adding CBD or THC to food or marketing them as dietary supplements because these substances are active ingredients in FDA-approved drugs (Epidiolex for CBD, Marinol for THC). The FDA has not clarified whether this prohibition extends to delta-8 THC and other hemp-derived cannabinoids not used in approved drugs. The agency issued a proposed rule in March 2024 that would establish a regulatory pathway for CBD products, but the proposal did not address intoxicating cannabinoids. As of June 2026, the rule remains in proposed status with no final action.

State Regulatory Approaches

States have adopted four primary regulatory models for hemp-derived intoxicants: Complete prohibition: Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, Vermont, and Washington have banned delta-8 THC and related intoxicating cannabinoids through legislation or administrative rules. These states generally prohibit all THC isomers or all "synthetically derived" cannabinoids regardless of source. Regulatory frameworks: California, Connecticut, Kentucky, Louisiana, Maryland, Oregon, and Virginia have established systems allowing hemp-derived intoxicants with testing requirements, potency limits, age restrictions, and licensing. California's AB 45, effective January 1, 2026, limits hemp products to 0.3 mg THC per serving and requires Proposition 65 warnings, third-party testing, and childproof packaging. Partial restrictions: Michigan, Minnesota, and Nevada allow hemp-derived cannabinoids but restrict sales channels, require registration, or impose labeling requirements. Minnesota's HF 4065, enacted in 2022, created a regulated hemp edibles market with 5 mg THC per serving limits and 50 mg per package limits. No specific regulation: Alabama, Florida, Georgia, Illinois, Indiana, Kansas, Missouri, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, West Virginia, Wisconsin, and Wyoming have not enacted hemp intoxicant-specific restrictions as of June 2026, though general drug laws may apply.

Market and Business Implications

The hemp-derived intoxicants market reached $2.8 billion in annual sales by 2025, with delta-8 THC representing approximately 65% of sales, followed by HHC at 18%, delta-10 at 9%, and other novel cannabinoids at 8%. Distribution channels differ markedly from state-licensed cannabis. Approximately 42% of hemp intoxicant sales occur through convenience stores and gas stations, 28% through smoke shops and vape stores, 18% through online retailers, and 12% through dedicated hemp stores, according to market research firm BDSA. This contrasts with licensed cannabis, which sells exclusively through state-approved dispensaries.

Impact on Licensed Cannabis Markets

Multi-state operators reported significant revenue impacts in states with large hemp intoxicant markets. Trulieve disclosed in its 2025 annual report that Florida operations experienced 12% year-over-year revenue decline attributed partly to "unregulated hemp competition," representing approximately $180 million in lost sales. Wholesale cannabis prices declined 35-45% in California, Michigan, and Oklahoma between 2022 and 2025, with industry analysts attributing 15-20% of the decline to hemp product competition rather than solely to licensed market oversupply. Vape cartridge prices showed the steepest declines, as delta-8 vapes sold for $15-25 compared to $35-60 for licensed cannabis vapes. The competitive pressure accelerated consolidation among licensed operators, with 47 multi-state operator acquisitions occurring in 2024-2025 as companies sought scale efficiencies to compete with lower-cost hemp alternatives.

Hemp Farming Economics

U.S. hemp cultivation reached 54,000 acres in 2025, down from a peak of 146,000 acres in 2019, with approximately 60% dedicated to cannabinoid production rather than fiber or grain. The shift toward cannabinoid-focused cultivation reflected higher returns, with CBD biomass fetching $300-600 per pound in 2025 compared to $0.60-1.20 per pound for fiber hemp. Kentucky led hemp cultivation with 12,400 acres, followed by North Carolina at 8,200 acres and Tennessee at 6,800 acres. These states' farmers supplied processors producing delta-8 and related compounds, creating economic dependency on the intoxicant market. Hemp farmer advocacy organizations including the Kentucky Hemp Association lobbied against state-level restrictions, arguing that cannabinoid markets provided essential revenue for rural communities. The National Hemp Association estimated that cannabinoid production supported 18,000 farming jobs and $1.2 billion in farm gate revenue in 2025.

Investment and Capital Flows

Venture capital investment in hemp-derived cannabinoid companies totaled $340 million between 2020 and 2025, according to PitchBook data, with investments concentrated in 2021-2022 before regulatory uncertainty slowed capital deployment. Major investments included a $50 million Series B round for 3Chi in 2022 and a $35 million Series A for Hometown Hero in 2021. Private equity firms largely avoided the sector due to federal legal ambiguity and reputational concerns, preferring to invest in state-licensed cannabis operators despite higher regulatory burdens. The lack of institutional capital limited hemp intoxicant companies' ability to implement quality control systems, conduct safety research, or develop sophisticated distribution networks. Public markets remained closed to hemp intoxicant manufacturers, with no companies achieving listings on major exchanges. This contrasted with Canadian cannabis companies and U.S. multi-state operators that accessed public capital markets despite federal prohibition.

Testing and Quality Control Economics

Third-party laboratory testing for hemp-derived products costs $150-400 per batch for a standard panel including potency, pesticides, heavy metals, and residual solvents. Industry surveys indicated that only 35-40% of hemp intoxicant manufacturers conducted comprehensive third-party testing as of 2025, compared to near-universal testing in state-licensed cannabis markets where regulations mandate it. The testing gap created a quality divide, with premium brands like 3Chi and Hometown Hero publishing certificates of analysis while budget brands sold untested products at lower prices. Consumers lacked reliable information to distinguish tested from untested products, as labeling requirements varied by state and enforcement was minimal. Independent testing by researchers at the University of Rochester in 2024 found that 52% of delta-8 products purchased from gas stations and convenience stores contained delta-9 THC levels exceeding 0.3%, making them federally illegal marijuana products. The study also found that 41% contained residual solvents and 23% contained heavy metals above safety thresholds.

What Experts Say

Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and cannabis specialist, described hemp-derived intoxicants as "the Wild West of cannabis products" in a 2024 interview with Harvard Health Publishing. Grinspoon noted that the lack of testing and quality control created unpredictable dosing and contamination risks that did not exist in regulated cannabis markets. Daniele Piomelli, a professor of pharmacology at the University of California, Irvine, and director of the Center for the Study of Cannabis, stated in congressional testimony that delta-8 THC produces intoxicating effects similar to delta-9 THC but that the chemical conversion process could introduce harmful byproducts. Piomelli emphasized that acid-catalyzed isomerization produces multiple THC isomers and degradation products that have not been studied for safety. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, argued in a 2025 policy paper that hemp-derived cannabinoids qualify as legal hemp derivatives under the Farm Bill and that federal regulation rather than prohibition would best protect consumers. Miller proposed FDA oversight modeled on dietary supplement regulations with good manufacturing practices, testing requirements, and adverse event reporting. Kevin Sabet, president of Smart Approaches to Marijuana, characterized hemp-derived intoxicants as "a loophole that's become a superhighway for unregulated drug sales" in testimony before the Michigan legislature in 2024. Sabet cited poison control data and emergency department visits as evidence that the products posed public health risks requiring immediate prohibition. Dr. Ryan Vandrey, a professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, conducted research published in the Journal of the American Medical Association in 2023 showing that delta-8 THC products produced dose-dependent intoxication and impairment comparable to delta-9 THC. Vandrey noted that the lack of standardized dosing information on product labels created risks of overconsumption, particularly for inexperienced users. Rod Kight, a cannabis attorney based in North Carolina, argued in legal analysis that the DEA's position on synthetically derived THC conflicts with the Farm Bill's broad definition of hemp derivatives. Kight contended that Congress intended to legalize all hemp-derived products meeting the 0.3% delta-9 THC threshold and that the DEA lacked authority to narrow that definition through rulemaking.

What's Next

The DEA faces a decision point by December 2026 on whether to finalize its August 2020 Interim Final Rule or modify its position on synthetically derived cannabinoids, following the standard notice-and-comment rulemaking process. The agency received over 5,000 public comments on the interim rule, with hemp industry stakeholders arguing for exemption of hemp-derived products and law enforcement organizations supporting the Schedule I classification. Congressional action remains possible through the 2028 Farm Bill reauthorization process, which will revisit hemp provisions. Representative Mary Miller of Illinois introduced the Hemp and Hemp-Derived Products Regulation Act in March 2026, which would establish FDA authority over hemp-derived cannabinoids with testing, labeling, and age restriction requirements. The bill had 37 cosponsors as of June 2026 but had not received committee hearings. State legislative sessions in 2027 will likely see continued regulatory activity, with Florida, Georgia, and Texas considering comprehensive hemp intoxicant frameworks. Industry observers expect 5-8 additional states to enact restrictions or regulations during 2027 legislative sessions. The FDA's proposed CBD rule, if finalized, could establish precedent for regulating other hemp-derived cannabinoids. The agency indicated in a March 2026 statement that it was "evaluating regulatory approaches for intoxicating hemp-derived substances" but provided no timeline for action. Federal court litigation may ultimately resolve the legal status of hemp-derived intoxicants if the DEA initiates enforcement actions that defendants challenge on Farm Bill grounds. As of June 2026, no federal court had issued a definitive ruling on whether chemically converted cannabinoids qualify as hemp derivatives or synthetically derived controlled substances. The hemp industry faces potential consolidation as regulatory uncertainty and quality concerns drive consumers toward established brands with testing protocols. Market analysts project that the top 10 brands will capture 60-70% market share by 2028, up from approximately 35% in 2025. Public health surveillance will continue through poison control centers, emergency departments, and the FDA's adverse event reporting system. The CDC announced in April 2026 that it would begin tracking hemp-derived cannabinoid exposures separately from marijuana exposures in its national surveillance systems, providing better data on health impacts.

Further Reading

• Agricultural Improvement Act of 2018 (Farm Bill), Public Law 115-334 - https://www.congress.gov/bill/115th-congress/house-bill/2
• DEA Interim Final Rule: Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639 (August 21, 2020) - https://www.federalregister.gov/documents/2020/08/21/2020-18188/implementation-of-the-agriculture-improvement-act-of-2018
• FDA Statement on Delta-8 THC (May 4, 2023) - https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc
• USDA Hemp Production Program Final Rule, 7 CFR Part 990 - https://www.ams.usda.gov/rules-regulations/hemp
• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html
• California Assembly Bill 45 (Hemp Products) - https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240AB45
• University of Rochester Delta-8 THC Product Testing Study (2024), Journal of Cannabis Research - https://jcannabisresearch.biomedcentral.com/
• American Association of Poison Control Centers National Poison Data System - https://www.aapcc.org/
• U.S. Hemp Roundtable Policy Positions - https://www.hempsupporter.com/
• National Hemp Association Industry Reports - https://www.nationalhempassociation.org/